mercoledì, 29 maggio 2024
23 Marzo 2018

Withdrawal of pain medicine flupirtine endorsed

March 23, 2018 – The CMDh has endorsed EMA’s recommendation to withdraw the marketing authorisation for the pain medicine flupirtine, because of the risk of serious liver injury. This means that the medicine will no longer be available. The EMA recommendation was the outcome of a review of flupirtine medicines which was started because liver problems continued to be reported even after measures were introduced in 2013 to manage this risk. These … (leggi tutto)